Health Challenge: Often opportunistic infections constitute the first manifestation of HIV infection and continue to cause morbidity and mortality in patients with HIV and AIDS throughout the world. Therefore, prevention and treatment of HIV-related opportunistic infection is an important part of care for people with HIV infection or AIDS. (Centre for Disease Control and Prevention, 2009)
Program Goal: To provide treatment for AIDS-related fungal infections in developing countries where HIV/AIDS is endemic.
Pfizer's Commitment: To provide Diflucan® (fluconazole) for the treatment of two fungal opportunistic infections associated with HIV and AIDS — cryptococcal meningitis and esophageal candidiasis, free of charge to government and nongovernmental organizations in developing countries with greater than 1% HIV and AIDS prevalence.
- Provided over $ 1.2 billion in medicine since 2000 to more than 2,400 sites in 63 countries in Africa, Asia, the Caribbean and Latin America
- Provided program materials to health care professionals to help improve patient management and medicine distribution.
- Developed on-line training modules to support the diagnosis and treatment of cryptococcal meningitis and esophageal candidiasis.
- On December 1, 2010 South Africa reached 10 years of successful implementation of the program, having distributed over 35 million Diflucan (fluconazole) treatments to over 700 participating health care facilities.
Partners: Direct Relief International (DRI), International Dispensary Association (IDA), Governments and non-governmental organizations (NGOs).
Region: Developing countries with priority given to those with greater than 1% HIV and AIDS prevalence. The program is active in Africa, Asia, the Caribbean and Latin America.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.